{"DataElement":{"publicId":"6733033","version":"1","preferredName":"Population Group Pharmacokinetic Study Emicizumab Therapy Coagulation Factor VIII Standard Half Life Bovine species Reagent Chromogenic Substrate Clotting Factor Assay","preferredDefinition":"A group of individuals united by a common factor (e.g., geographic location, ethnicity, disease, age, gender)_A study of the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body._A humanized, immunoglobulin G4 (IgG4), bispecific monoclonal antibody against both the activated coagulation factor IX (FIXa) and factor X (FX) that can be used for the treatment of haemophilia A (HA). Upon administration, emicizumab targets and binds to both the FIXa and to FX, thereby bridging FIXa and FX, activating FX, and allowing for the activation and continuation of the coagulation cascade. FX is normally activated by  coagulation factor VIII (FVIII); FVIII is missing in HA patients._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._Coagulation factor VIII (2351 aa, ~267 kDa) is encoded by the human F8 gene. This protein plays a role in the modulation of coagulation factor IX activity and blood coagulation._The amount of time needed for a material to lose half of its physical, chemical, or biological activity._A document, established by consensus and approved by a recognized body, that provides, for common and repeated use, rules, guidelines or characteristics for activities or their results._A reagent containing purified coagulation factors (FIXa, FX and thrombin) in optimal concentrations is added to test plasma in the first stage, which does not rely on the extrinsic or intrinsic initiation pathways as the thrombin activates FVIII. The amount of FXa generated in the first stage is measured by its action on a specific chromogenic substrate, which releases a chromophore upon cleavage. The color intensity produced is directly proportional to the amount of FXa, which in turn is directly proportional to the FVIII activity in the sample.","longName":"6733028v1.0:6732978v1.0","context":"PhenX","contextVersion":"1","DataElementConcept":{"publicId":"6733028","version":"1","preferredName":"Population Group Pharmacokinetic Study Emicizumab Therapy Coagulation Factor VIII Standard Half Life","preferredDefinition":"A group of individuals united by a common factor (e.g., geographic location, ethnicity, disease, age, gender)_A study of the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body._A humanized, immunoglobulin G4 (IgG4), bispecific monoclonal antibody against both the activated coagulation factor IX (FIXa) and factor X (FX) that can be used for the treatment of haemophilia A (HA). Upon administration, emicizumab targets and binds to both the FIXa and to FX, thereby bridging FIXa and FX, activating FX, and allowing for the activation and continuation of the coagulation cascade. FX is normally activated by  coagulation factor VIII (FVIII); FVIII is missing in HA patients._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._Coagulation factor VIII (2351 aa, ~267 kDa) is encoded by the human F8 gene. This protein plays a role in the modulation of coagulation factor IX activity and blood coagulation._The amount of time needed for a material to lose half of its physical, chemical, or biological activity._A document, established by consensus and approved by a recognized body, that provides, for common and repeated use, rules, guidelines or characteristics for activities or their results.","longName":"6706636v1.0:6733026v1.0","context":"PhenX","contextVersion":"1","ObjectClass":{"publicId":"6706636","version":"1","preferredName":"Population Group Pharmacokinetic Study","preferredDefinition":"A group of individuals united by a common factor (e.g., geographic location, ethnicity, disease, age, gender):A study of the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body.","longName":"C17005:C49663","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Population Group","conceptCode":"C17005","definition":"A group of individuals united by a common factor (e.g., geographic location, ethnicity, disease, age, gender)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pharmacokinetic Study","conceptCode":"C49663","definition":"A study of the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"871581F0-C744-1C0F-E053-F662850AAFE3","latestVersionIndicator":"Yes","beginDate":"2019-04-21","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-21","modifiedBy":"ONEDATA","dateModified":"2019-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6733026","version":"1","preferredName":"Emicizumab Therapeutic Procedure Coagulation Factor VIII Standard Half Life","preferredDefinition":"A humanized, immunoglobulin G4 (IgG4), bispecific monoclonal antibody against both the activated coagulation factor IX (FIXa) and factor X (FX) that can be used for the treatment of haemophilia A (HA). Upon administration, emicizumab targets and binds to both the FIXa and to FX, thereby bridging FIXa and FX, activating FX, and allowing for the activation and continuation of the coagulation cascade. FX is normally activated by  coagulation factor VIII (FVIII); FVIII is missing in HA patients.:An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.:Coagulation factor VIII (2351 aa, ~267 kDa) is encoded by the human F8 gene. This protein plays a role in the modulation of coagulation factor IX activity and blood coagulation.:A document, established by consensus and approved by a recognized body, that provides, for common and repeated use, rules, guidelines or characteristics for activities or their results.:The amount of time needed for a material to lose half of its physical, chemical, or biological activity.","longName":"6733026v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Emicizumab","conceptCode":"C159541","definition":"A humanized, immunoglobulin G4 (IgG4), bispecific monoclonal antibody against both the activated coagulation factor IX (FIXa) and factor X (FX) that can be used for the treatment of hemophilia A (HA). Upon administration, emicizumab targets and binds to both the FIXa and to FX, thereby bridging FIXa and FX, activating FX, and allowing for the activation and continuation of the coagulation cascade. FX is normally activated by coagulation factor VIII (FVIII); FVIII is missing in HA patients.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Coagulation Factor VIII","conceptCode":"C16571","definition":"Coagulation factor VIII (2351 aa, ~267 kDa) is encoded by the human F8 gene. This protein plays a role in the modulation of coagulation factor IX activity and blood coagulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Standard","conceptCode":"C81893","definition":"A document, established by consensus and approved by a recognized body, that provides, for common and repeated use, rules, guidelines or characteristics for activities or their results.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Half Life","conceptCode":"C70916","definition":"The amount of time needed for a material to lose half of its physical, chemical, or biological activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"877037F4-E310-4FCC-E053-F662850A456F","latestVersionIndicator":"Yes","beginDate":"2019-04-26","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"877037F4-E321-4FCC-E053-F662850A456F","latestVersionIndicator":"Yes","beginDate":"2019-04-26","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-26","modifiedBy":"PANH","dateModified":"2019-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6732978","version":"1","preferredName":"Bovine species Reagent Chromogenic Substrate Clotting Factor Assay","preferredDefinition":"No Value Exists_Any natural or synthetic substance used in a chemical or biological reaction in order to produce, identify, or measure another substance._A reagent containing purified coagulation factors (FIXa, FX and thrombin) in optimal concentrations is added to test plasma in the first stage, which does not rely on the extrinsic or intrinsic initiation pathways as the thrombin activates FVIII. The amount of FXa generated in the first stage is measured by its action on a specific chromogenic substrate, which releases a chromophore upon cleavage. The color intensity produced is directly proportional to the amount of FXa, which in turn is directly proportional to the FVIII activity in the sample.","longName":"6732978v1.0","context":"PhenX","contextVersion":"1","type":"Non-enumerated","dataType":"NUMBER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6732977","version":"1","preferredName":"Bovine species Reagent Chromogenic Substrate Clotting Factor Assay","preferredDefinition":"No Value Exists:Any natural or synthetic substance used in a chemical or biological reaction in order to produce, identify, or measure another substance.:A reagent containing purified coagulation factors (FIXa, FX and thrombin) in optimal concentrations is added to test plasma in the first stage, which does not rely on the extrinsic or intrinsic initiation pathways as the thrombin activates FVIII. The amount of FXa generated in the first stage is measured by its action on a specific chromogenic substrate, which releases a chromophore upon cleavage. The color intensity produced is directly proportional to the amount of FXa, which in turn is directly proportional to the FVIII activity in the sample.","longName":"L-80100:C802:C159552","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bovine species","conceptCode":"L-80100","definition":"No Value Exists","evsSource":"SNOMED-CT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Reagent","conceptCode":"C802","definition":"Any natural or synthetic substance used in a chemical or biological reaction in order to produce, identify, or measure another substance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Chromogenic Substrate Clotting Factor Assay","conceptCode":"C159552","definition":"A reagent containing purified coagulation factors (FIXa, FX and thrombin) in optimal concentrations is added to test plasma in the first stage, which does not rely on the extrinsic or intrinsic initiation pathways as the thrombin activates FVIII. The amount of FXa generated in the first stage is measured by its action on a specific chromogenic substrate, which releases a chromophore upon cleavage. The color intensity produced is directly proportional to the amount of FXa, which in turn is directly proportional to the FVIII activity in the sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87708EBF-046E-43ED-E053-F662850A03FD","latestVersionIndicator":"Yes","beginDate":"2019-04-26","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87708EBF-047F-43ED-E053-F662850A03FD","latestVersionIndicator":"Yes","beginDate":"2019-04-26","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-26","modifiedBy":"PANH","dateModified":"2019-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2793652","version":"1","longName":"PhenX","context":"PhenX","ClassificationSchemeItems":[{"publicId":"6641385","version":"1","longName":"Hemophilia","context":"PhenX"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Data Element Population Group Pharmacokinetic Study Emicizumab Therapy Coagulation Factor VIII Standard Half Life Bovine species Reagent Chromogenic Substrate Clotting Factor Assay does not have Preferred Question Text","type":"Preferred Question Text","description":"Data Element Population Group Pharmacokinetic Study Emicizumab Therapy Coagulation Factor VIII Standard Half Life Bovine species Reagent Chromogenic Substrate Clotting Factor Assay does not have Preferred Question Text","url":null,"context":"PhenX"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"87706CAE-9B4E-4FBC-E053-F662850AA9BE","latestVersionIndicator":"Yes","beginDate":"2019-04-26","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-26","modifiedBy":"PANH","dateModified":"2020-06-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}